Abstract
The Hippo-signaling effector YAP1 was recently found to compensate for oncogenic RAS in certain neoplasms, suggesting so far unanticipated molecular interplays between these major signaling routes. A new study in this issue of The EMBO Journal details KRAS-dependent control of YAP1 stability as well as positive feedback regulation via the RAS/YAP1/EGFR-ligand axis as novel molecular mechanisms that could become exploitable for therapeutic strategies.
MeSH terms
-
Adaptor Proteins, Signal Transducing / metabolism*
-
Cell Transformation, Neoplastic / metabolism*
-
Hippo Signaling Pathway
-
Humans
-
Phosphoproteins / metabolism*
-
Protein Serine-Threonine Kinases / metabolism*
-
Signal Transduction*
-
Transcription Factors
-
YAP-Signaling Proteins
-
ras Proteins / metabolism*
Substances
-
Adaptor Proteins, Signal Transducing
-
Phosphoproteins
-
Transcription Factors
-
YAP-Signaling Proteins
-
YAP1 protein, human
-
Protein Serine-Threonine Kinases
-
ras Proteins